Zevra Therapeutics (ZVRA) Operating Leases (2019 - 2026)

Zevra Therapeutics has reported Operating Leases for 8 years, with the latest figure at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 0.95% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (down 0.95% YoY), and the FY2025 full-year result was $1.3 million, up 61.36% from the prior year.
• Operating Leases for Q1 2026 stood at $1.1 million, down from $1.3 million in the prior quarter.
• The five-year high for Operating Leases was $1.4 million in Q3 2025, with the low at $456000.0 in Q4 2023.
• Historically, Operating Leases has averaged $936692.3 across 5 years, with a median of $1.1 million in 2025.
• Annual changes were most pronounced in 2022 — Operating Leases plunged 46.91% — and 2025, when it surged 191.3%.
• Zevra Therapeutics' Operating Leases stood at $843000.0 in 2022, then slumped by 45.91% to $456000.0 in 2023, then surged by 73.68% to $792000.0 in 2024, then surged by 61.36% to $1.3 million in 2025, then fell by 10.25% to $1.1 million in 2026.
• The last three Operating Leases figures came in at $1.1 million (Q1 2026), $1.3 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.